Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine, Mitsubishi Pharma Partner on Biomarker Discovery for Muscle Toxicity

NEW YORK, March 28 (GenomeWeb News) - BG Medicine said today that it has signed a collaborative research agreement with Mitsubishi Pharma of Osaka, Japan, to discover biomarkers associated with muscle toxicity in lipid-lowering compounds.


BG Medicine said it will use proteomics, metabolomics, and computational analyses to study the molecular effects of selected lipid-lowering agents on skeletal muscle and to identify specific plasma biomarkers of these effects.


Mitsubishi Pharma will contribute transcript, clinical chemistry, and histopathology data to the project.


BG Medicine said that it will jointly own "certain rights" to the project data and biomarkers with Mitsubishi Pharma, but additional terms of the agreement were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.